Streamlining Regulations for Good Manufacturing Practices for Hearing Aids; Public Workshop; Request for Comments, 784-786 [2016-00065]
Download as PDF
784
Federal Register / Vol. 81, No. 4 / Thursday, January 7, 2016 / Notices
Estimated Total Annual Burden
Hours: 540.
In compliance with the requirements
of Section 506(c)(2)(A) of the Paperwork
Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Planning, Research
and Evaluation, 370 L’Enfant
Promenade SW., Washington, DC 20447,
Attn: ACF Reports Clearance Officer.
Email address: infocollection@
acf.hhs.gov. All requests should be
identified by the title of the information
collection.
The Department specifically requests
comments on: (a) Whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2016–00054 Filed 1–6–16; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–N–4602]
Streamlining Regulations for Good
Manufacturing Practices for Hearing
Aids; Public Workshop; Request for
Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice of public workshop;
request for comments.
discussed is the appropriate level of
good manufacturing practices (GMPs)
regulation to ensure the safety and
effectiveness of air-conduction hearing
aid devices.
DATES: The public workshop will be
held on April 21, 2016, from 8:30 a.m.
to 5 p.m. Submit either electronic or
written comments on the public
workshop by May 19, 2016.
ADDRESSES: The public workshop will
be held at FDA’s White Oak Campus,
10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm.
1503), Silver Spring, MD 20993–0002.
Entrance for the public meeting
participants (non-FDA employees) is
through Building 1 where routine
security check procedures will be
performed. For parking and security
information, please refer to https://
www.fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm.
You may submit comments as
follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
rmajette on DSK2TPTVN1PROD with NOTICES
ACTION:
Written/Paper Submissions
The Food and Drug
Administration (FDA) is announcing the
following public workshop entitled
‘‘Streamlining Regulations for Good
Manufacturing Practices (GMPs) for
Hearing Aids.’’ The topic to be
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
SUMMARY:
VerDate Sep<11>2014
18:26 Jan 06, 2016
Jkt 238001
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2015–N–4602 for ‘‘Streamlining
Regulations for Good Manufacturing
Practices (GMPs) for Hearing Aids.’’
Received comments will be placed in
the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
E:\FR\FM\07JAN1.SGM
07JAN1
Federal Register / Vol. 81, No. 4 / Thursday, January 7, 2016 / Notices
FOR FURTHER INFORMATION CONTACT:
Srinivas Nandkumar, Food and Drug
Administration, Center for Devices and
Radiological Health, Bldg. 66, Rm. 2436,
10903 New Hampshire Ave., Silver
Spring, MD 20993, 301–796–6480, FAX:
301–847–8126, Srinivas.nandkumar@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
rmajette on DSK2TPTVN1PROD with NOTICES
Over 35 million people in the United
States have some degree of hearing loss.
However, it is estimated that only 20
percent of individuals who could
benefit from hearing aids are using
them. There are several well-recognized
reasons or ‘‘barriers’’ causing underuse
of hearing aids, including the high cost
of these devices, the stigma associated
with hearing aid use, and the fact that
hearing aids do not restore hearing to
normal the way that eyeglasses can
correct visual problems. On October 26,
2015, the President’s Council on
Science and Technology (PCAST)
issued a report in recognition of the
substantial national public health
problem of barriers to accessibility and
affordability of hearing aids for
Americans with ‘‘normal, age-related,
progressive, mild-to-moderate hearing
loss’’ and the underuse of these devices
in the older American population. The
report includes a number of
recommendations regarding possible
modifications to Federal Regulation of
hearing aids by FDA and the Federal
Trade Commission, which PCAST
believes could ‘‘enhance the pace of
innovation and level of competition,
leading to rapid decrease in cost and
improvement in capability,
convenience, and use of assistive
hearing devices’’ (https://
www.whitehouse.gov/sites/default/files/
microsites/ostp/PCAST/pcast_hearing_
tech_letterreport_final2.pdf). Among
these recommendations, PCAST
recommended FDA exempt hearing aids
indicated for bilateral, gradual onset,
mild-to-moderate age-related hearing
loss from the Quality System Regulation
(QSReg) in its present form and
‘‘substitute compliance with standards
for product quality and recordkeeping
appropriate for the consumer electronics
industry, developed by an appropriate
third-party organization and approved
by FDA.’’
II. Topics for Discussion at the Public
Workshop
In response to PCAST’s
recommendations outlined in this
document, the workshop will discuss
the current GMPs that are required
under the QSReg and gather suggestions
VerDate Sep<11>2014
14:27 Jan 06, 2016
Jkt 238001
for an alternative model for quality
verification. Invited speakers will
discuss how the current regulations may
be unsuitable for air-conduction hearing
aids and may hinder innovation, reduce
competition, and lead to increased cost
and reduced use of these devices by
Americans with age-related hearing loss.
Additionally, the potential exemption of
hearing aids from the QSReg, through
use of alternative standards developed
in collaboration with key stakeholders
and standards development
organizations, and recognized by FDA
and recordkeeping to ensure product
quality, will be discussed.
Registration: Registration is free and
available on a first-come, first-served
basis. Persons interested in attending
this public workshop must register
online by 4 p.m. on April 13, 2016.
Early registration is recommended
because facilities are limited and,
therefore, FDA may limit the number of
participants from each organization. If
time and space permits, onsite
registration on the day of the public
workshop will be provided beginning at
7:30 a.m.
If you need special accommodations
due to a disability, please contact Susan
Monahan, Center for Devices and
Radiological Health, Office of
Communication and Education, 301–
796–5661, susan.monahan@fda.hhs.gov
no later than April 7, 2016.
To register for the public workshop,
please visit FDA’s Medical Devices
News & Events—Workshops &
Conferences calendar at https://
www.fda.gov/MedicalDevices/
NewsEvents/WorkshopsConferences/
default.htm. (Select this meeting/public
workshop from the posted events list.)
Please provide complete contact
information for each attendee, including
name, title, affiliation, email, and
telephone number. Those without
Internet access should contact Susan
Monahan (contact for special
accommodations) to register. Registrants
will receive confirmation after they have
been accepted. You will be notified if
you are on a waiting list.
Streaming Webcast of the Public
Workshop: This public workshop will
also be Webcast. The Webcast link will
be available on the workshop Web page
after April 14, 2016. Please visit FDA’s
Medical Devices News & Events—
Workshops & Conferences calendar at
https://www.fda.gov/MedicalDevices/
NewsEvents/WorkshopsConferences/
default.htm. (Select this public
workshop from the posted events list.)
If you have never attended a Connect
Pro event before, test your connection at
https://collaboration.fda.gov/common/
help/en/support/meeting_test.htm. To
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
785
get a quick overview of the Connect Pro
program, visit https://www.adobe.com/
go/connectpro_overview. FDA has
verified the Web site addresses in this
document, as of the date this document
publishes in the Federal Register, but
Web sites are subject to change over
time.
Requests for Oral Presentations: This
public workshop includes a public
comment session and topic-focused
sessions. During online registration, you
may indicate if you wish to present
during a public comment session or
participate in a specific session, and
which topics you wish to address. FDA
has included general topics in this
document. FDA will do its best to
accommodate requests to make public
comments. Individuals and
organizations with common interests are
urged to consolidate or coordinate their
presentations, and request time for a
joint presentation, or submit requests for
designated representatives to participate
in the focused sessions. Following the
close of registration, FDA will
determine the amount of time allotted to
each presenter and the approximate
time each oral presentation is to begin,
and will select and notify participants
by April 15, 2016. All requests to make
oral presentations must be received by
the close of registration on April 13,
2016, 4 p.m. If selected for presentation,
any presentation materials must be
emailed to Srinivas Nandkumar (see FOR
FURTHER INFORMATION CONTACT) no later
than April 19, 2016. No commercial or
promotional material will be permitted
to be presented or distributed at the
public workshop.
FDA is holding this public workshop
to obtain information on the appropriate
level of good manufacturing practices
for hearing aids. In order to permit the
widest possible opportunity to obtain
public comment, FDA is soliciting
either electronic or written comments
on all aspects of the public workshop
topics. The deadline for submitting
comments related to this public
workshop is May 19, 2016.
Transcripts: Please be advised that as
soon as a transcript is available, it will
be accessible at https://
www.regulations.gov. It may be viewed
at the Division of Dockets Management
(see ADDRESSES). A transcript will also
be available in either hardcopy or on
CD–ROM, after submission of a
Freedom of Information request. The
Freedom of Information office address is
available on the Agency’s Web site at
https://www.fda.gov. A link to the
transcripts will also be available
approximately 45 days after the public
workshop on the Internet at https://
www.fda.gov/MedicalDevices/
E:\FR\FM\07JAN1.SGM
07JAN1
786
Federal Register / Vol. 81, No. 4 / Thursday, January 7, 2016 / Notices
NewsEvents/WorkshopsConferences/
default.htm. (Select this meeting/public
workshop from the posted events list.)
Dated: December 31, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–00065 Filed 1–6–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–D–1295]
Regulatory Requirements for Hearing
Aid Devices and Personal Sound
Amplification Products; Draft
Guidance for Industry and Food and
Drug Administration Staff; Reopening
of the Comment Period
AGENCY:
Food and Drug Administration,
HHS.
Notice; reopening of the
comment period.
ACTION:
The Food and Drug
Administration (FDA or Agency) is
reopening the comment period for the
draft guidance entitled ‘‘Regulatory
Requirements for Hearing Aid Devices
and Personal Sound Amplification
Products.’’ A notice of availability
requesting comments on the draft
guidance document appeared in the
Federal Register of November 7, 2013.
The Agency is reopening the comment
period to receive updated comments
and any new information.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency
considers your comment of this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance by May 6, 2016.
ADDRESSES: You may submit comments
as follows:
SUMMARY:
rmajette on DSK2TPTVN1PROD with NOTICES
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
VerDate Sep<11>2014
18:29 Jan 06, 2016
Jkt 238001
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2013–D–1295 for ‘‘Regulatory
Requirements for Hearing Aid Devices
and Personal Sound Amplification
Products’’ draft guidance. Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
An electronic copy of the draft
guidance document is available for
download from the Internet. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
draft guidance. Submit written requests
for a single hard copy of the draft
guidance document entitled ‘‘Regulatory
Requirements for Hearing Aid Devices
and Personal Sound Amplification
Products’’ to the Office of the Center
Director, Guidance and Policy
Development, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5431, Silver Spring,
MD 20993–0002. Send one selfaddressed adhesive label to assist that
office in processing your request.
FOR FURTHER INFORMATION CONTACT: Eric
Mann, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 2438, Silver Spring,
MD 20993–0002, 301–796–6460.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of November 7,
2013 (78 FR 66940), FDA published a
notice of availability with a 90-day
comment period to request comments
on the draft guidance entitled
‘‘Regulatory Requirements for Hearing
Aid Devices and Personal Sound
Amplification Products.’’
Since issuance of the November 7,
2013, draft guidance entitled
‘‘Regulatory Requirements for Hearing
Aid Devices and Personal Sound
Amplification Products,’’ FDA has
become aware of other efforts by the
President’s Council of Advisors on
Science and Technology (PCAST) and
E:\FR\FM\07JAN1.SGM
07JAN1
Agencies
[Federal Register Volume 81, Number 4 (Thursday, January 7, 2016)]
[Notices]
[Pages 784-786]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-00065]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2015-N-4602]
Streamlining Regulations for Good Manufacturing Practices for
Hearing Aids; Public Workshop; Request for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public workshop; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
following public workshop entitled ``Streamlining Regulations for Good
Manufacturing Practices (GMPs) for Hearing Aids.'' The topic to be
discussed is the appropriate level of good manufacturing practices
(GMPs) regulation to ensure the safety and effectiveness of air-
conduction hearing aid devices.
DATES: The public workshop will be held on April 21, 2016, from 8:30
a.m. to 5 p.m. Submit either electronic or written comments on the
public workshop by May 19, 2016.
ADDRESSES: The public workshop will be held at FDA's White Oak Campus,
10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room
(Rm. 1503), Silver Spring, MD 20993-0002. Entrance for the public
meeting participants (non-FDA employees) is through Building 1 where
routine security check procedures will be performed. For parking and
security information, please refer to https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.
You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2015-N-4602 for ``Streamlining Regulations for Good Manufacturing
Practices (GMPs) for Hearing Aids.'' Received comments will be placed
in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at https://www.regulations.gov or at
the Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.fda.gov/regulatoryinformation/dockets/default.htm.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
[[Page 785]]
FOR FURTHER INFORMATION CONTACT: Srinivas Nandkumar, Food and Drug
Administration, Center for Devices and Radiological Health, Bldg. 66,
Rm. 2436, 10903 New Hampshire Ave., Silver Spring, MD 20993, 301-796-
6480, FAX: 301-847-8126, Srinivas.nandkumar@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Over 35 million people in the United States have some degree of
hearing loss. However, it is estimated that only 20 percent of
individuals who could benefit from hearing aids are using them. There
are several well-recognized reasons or ``barriers'' causing underuse of
hearing aids, including the high cost of these devices, the stigma
associated with hearing aid use, and the fact that hearing aids do not
restore hearing to normal the way that eyeglasses can correct visual
problems. On October 26, 2015, the President's Council on Science and
Technology (PCAST) issued a report in recognition of the substantial
national public health problem of barriers to accessibility and
affordability of hearing aids for Americans with ``normal, age-related,
progressive, mild-to-moderate hearing loss'' and the underuse of these
devices in the older American population. The report includes a number
of recommendations regarding possible modifications to Federal
Regulation of hearing aids by FDA and the Federal Trade Commission,
which PCAST believes could ``enhance the pace of innovation and level
of competition, leading to rapid decrease in cost and improvement in
capability, convenience, and use of assistive hearing devices''
(https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_hearing_tech_letterreport_final2.pdf). Among these
recommendations, PCAST recommended FDA exempt hearing aids indicated
for bilateral, gradual onset, mild-to-moderate age-related hearing loss
from the Quality System Regulation (QSReg) in its present form and
``substitute compliance with standards for product quality and
recordkeeping appropriate for the consumer electronics industry,
developed by an appropriate third-party organization and approved by
FDA.''
II. Topics for Discussion at the Public Workshop
In response to PCAST's recommendations outlined in this document,
the workshop will discuss the current GMPs that are required under the
QSReg and gather suggestions for an alternative model for quality
verification. Invited speakers will discuss how the current regulations
may be unsuitable for air-conduction hearing aids and may hinder
innovation, reduce competition, and lead to increased cost and reduced
use of these devices by Americans with age-related hearing loss.
Additionally, the potential exemption of hearing aids from the QSReg,
through use of alternative standards developed in collaboration with
key stakeholders and standards development organizations, and
recognized by FDA and recordkeeping to ensure product quality, will be
discussed.
Registration: Registration is free and available on a first-come,
first-served basis. Persons interested in attending this public
workshop must register online by 4 p.m. on April 13, 2016. Early
registration is recommended because facilities are limited and,
therefore, FDA may limit the number of participants from each
organization. If time and space permits, onsite registration on the day
of the public workshop will be provided beginning at 7:30 a.m.
If you need special accommodations due to a disability, please
contact Susan Monahan, Center for Devices and Radiological Health,
Office of Communication and Education, 301-796-5661,
susan.monahan@fda.hhs.gov no later than April 7, 2016.
To register for the public workshop, please visit FDA's Medical
Devices News & Events--Workshops & Conferences calendar at https://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm.
(Select this meeting/public workshop from the posted events list.)
Please provide complete contact information for each attendee,
including name, title, affiliation, email, and telephone number. Those
without Internet access should contact Susan Monahan (contact for
special accommodations) to register. Registrants will receive
confirmation after they have been accepted. You will be notified if you
are on a waiting list.
Streaming Webcast of the Public Workshop: This public workshop will
also be Webcast. The Webcast link will be available on the workshop Web
page after April 14, 2016. Please visit FDA's Medical Devices News &
Events--Workshops & Conferences calendar at https://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm. (Select
this public workshop from the posted events list.) If you have never
attended a Connect Pro event before, test your connection at https://collaboration.fda.gov/common/help/en/support/meeting_test.htm. To get a
quick overview of the Connect Pro program, visit https://www.adobe.com/go/connectpro_overview. FDA has verified the Web site addresses in this
document, as of the date this document publishes in the Federal
Register, but Web sites are subject to change over time.
Requests for Oral Presentations: This public workshop includes a
public comment session and topic-focused sessions. During online
registration, you may indicate if you wish to present during a public
comment session or participate in a specific session, and which topics
you wish to address. FDA has included general topics in this document.
FDA will do its best to accommodate requests to make public comments.
Individuals and organizations with common interests are urged to
consolidate or coordinate their presentations, and request time for a
joint presentation, or submit requests for designated representatives
to participate in the focused sessions. Following the close of
registration, FDA will determine the amount of time allotted to each
presenter and the approximate time each oral presentation is to begin,
and will select and notify participants by April 15, 2016. All requests
to make oral presentations must be received by the close of
registration on April 13, 2016, 4 p.m. If selected for presentation,
any presentation materials must be emailed to Srinivas Nandkumar (see
FOR FURTHER INFORMATION CONTACT) no later than April 19, 2016. No
commercial or promotional material will be permitted to be presented or
distributed at the public workshop.
FDA is holding this public workshop to obtain information on the
appropriate level of good manufacturing practices for hearing aids. In
order to permit the widest possible opportunity to obtain public
comment, FDA is soliciting either electronic or written comments on all
aspects of the public workshop topics. The deadline for submitting
comments related to this public workshop is May 19, 2016.
Transcripts: Please be advised that as soon as a transcript is
available, it will be accessible at https://www.regulations.gov. It may
be viewed at the Division of Dockets Management (see ADDRESSES). A
transcript will also be available in either hardcopy or on CD-ROM,
after submission of a Freedom of Information request. The Freedom of
Information office address is available on the Agency's Web site at
https://www.fda.gov. A link to the transcripts will also be available
approximately 45 days after the public workshop on the Internet at
https://www.fda.gov/MedicalDevices/
[[Page 786]]
NewsEvents/WorkshopsConferences/default.htm. (Select this meeting/
public workshop from the posted events list.)
Dated: December 31, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-00065 Filed 1-6-16; 8:45 am]
BILLING CODE 4164-01-P